116 related articles for article (PubMed ID: 31607566)
1. L-carnitine supplementation attenuates NAFLD progression and cardiac dysfunction in a mouse model fed with methionine and choline-deficient diet.
Mollica G; Senesi P; Codella R; Vacante F; Montesano A; Luzi L; Terruzzi I
Dig Liver Dis; 2020 Mar; 52(3):314-323. PubMed ID: 31607566
[TBL] [Abstract][Full Text] [Related]
2. Roflumilast ameliorates GAN diet-induced non-alcoholic fatty liver disease by reducing hepatic steatosis and fibrosis in ob/ob mice.
Wang B; Zhu X; Yu S; Xue H; Deng L; Zhang Y; Zhang Y; Liu Y
Biochem Biophys Res Commun; 2024 Aug; 722():150170. PubMed ID: 38797152
[TBL] [Abstract][Full Text] [Related]
3. Targeting Liver Fibrosis with a Cell-penetrating Protease-activated Receptor-2 (PAR2) Pepducin.
Shearer AM; Rana R; Austin K; Baleja JD; Nguyen N; Bohm A; Covic L; Kuliopulos A
J Biol Chem; 2016 Oct; 291(44):23188-23198. PubMed ID: 27613872
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of hepatic p63 ameliorates steatohepatitis with fibrosis in mice.
Fondevila MF; Novoa E; Fernandez U; Dorta V; Parracho T; Kreimeyer H; Garcia-Vence M; Chantada-Vazquez MP; Bravo SB; Porteiro B; Cabaleiro A; Koning M; Senra A; Souto Y; Verheij J; Guallar D; Fidalgo M; Meijnikman AS; da Silva Lima N; Dieguez C; Gonzalez-Rellan MJ; Nogueiras R
Mol Metab; 2024 May; 85():101962. PubMed ID: 38815625
[TBL] [Abstract][Full Text] [Related]
5. Potential utility of l-carnitine for preventing liver tumors derived from metabolic dysfunction-associated steatohepatitis.
Lyu J; Okada H; Sunagozaka H; Kawaguchi K; Shimakami T; Nio K; Murai K; Shirasaki T; Yoshida M; Arai K; Yamashita T; Tanaka T; Harada K; Takamura T; Kaneko S; Yamashita T; Honda M
Hepatol Commun; 2024 May; 8(5):. PubMed ID: 38619434
[TBL] [Abstract][Full Text] [Related]
6. Functional Food Chemical Ingredient Strategies for Non-alcoholic Fatty Liver Disease (NAFLD) and Hepatic Fibrosis: Chemical Properties, Health Benefits, Action, and Application.
Yu C; Guo X; Cui X; Su G; Wang H
Curr Nutr Rep; 2024 Mar; 13(1):1-14. PubMed ID: 38172459
[TBL] [Abstract][Full Text] [Related]
7. Effects of Ganjianglingzhu Decoction on Lean Non-Alcoholic Fatty Liver Disease in Mice Based on Untargeted Metabolomics.
Tang N; Ji L; Shi X; Xiong Y; Xiong X; Zhao H; Song H; Wang J; Zhang L; You S; Ji G; Liu B; Wu N
Pharmaceuticals (Basel); 2024 Apr; 17(4):. PubMed ID: 38675462
[TBL] [Abstract][Full Text] [Related]
8. The acute effect of metabolic cofactor supplementation: a potential therapeutic strategy against non-alcoholic fatty liver disease.
Zhang C; Bjornson E; Arif M; Tebani A; Lovric A; Benfeitas R; Ozcan M; Juszczak K; Kim W; Kim JT; Bidkhori G; Ståhlman M; Bergh PO; Adiels M; Turkez H; Taskinen MR; Bosley J; Marschall HU; Nielsen J; Uhlén M; Borén J; Mardinoglu A
Mol Syst Biol; 2020 Apr; 16(4):e9495. PubMed ID: 32337855
[TBL] [Abstract][Full Text] [Related]
9. Cardiac lipotoxicity and fibrosis underlie impaired contractility in a mouse model of metabolic dysfunction-associated steatotic liver disease.
Badmus OO; da Silva AA; Li X; Taylor LC; Greer JR; Wasson AR; McGowan KE; Patel PR; Stec DE
FASEB Bioadv; 2024 May; 6(5):131-142. PubMed ID: 38706754
[TBL] [Abstract][Full Text] [Related]
10. L-Carnitine counteracts in vitro fructose-induced hepatic steatosis through targeting oxidative stress markers.
Montesano A; Senesi P; Vacante F; Mollica G; Benedini S; Mariotti M; Luzi L; Terruzzi I
J Endocrinol Invest; 2020 Apr; 43(4):493-503. PubMed ID: 31705397
[TBL] [Abstract][Full Text] [Related]
11. Adipokines, Myokines, and Cardiokines: The Role of Nutritional Interventions.
Senesi P; Luzi L; Terruzzi I
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33171610
[TBL] [Abstract][Full Text] [Related]
12. Safety and tolerability of repeated sessions of deep transcranial magnetic stimulation in obesity.
Ferrulli A; Massarini S; Macrì C; Luzi L
Endocrine; 2021 Feb; 71(2):331-343. PubMed ID: 32964308
[TBL] [Abstract][Full Text] [Related]
13. NAFLD and Atherosclerosis: Two Sides of the Same Dysmetabolic Coin?
Stols-Gonçalves D; Hovingh GK; Nieuwdorp M; Holleboom AG
Trends Endocrinol Metab; 2019 Dec; 30(12):891-902. PubMed ID: 31630897
[TBL] [Abstract][Full Text] [Related]
14. ATF3/SPI1/SLC31A1 Signaling Promotes Cuproptosis Induced by Advanced Glycosylation End Products in Diabetic Myocardial Injury.
Huo S; Wang Q; Shi W; Peng L; Jiang Y; Zhu M; Guo J; Peng D; Wang M; Men L; Huang B; Lv J; Lin L
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675183
[TBL] [Abstract][Full Text] [Related]
15. The Molecular Mechanisms of Defective Copper Metabolism in Diabetic Cardiomyopathy.
Cui X; Wang Y; Liu H; Shi M; Wang J; Wang Y
Oxid Med Cell Longev; 2022; 2022():5418376. PubMed ID: 36238639
[TBL] [Abstract][Full Text] [Related]
16. Essential metals in health and disease.
Jomova K; Makova M; Alomar SY; Alwasel SH; Nepovimova E; Kuca K; Rhodes CJ; Valko M
Chem Biol Interact; 2022 Nov; 367():110173. PubMed ID: 36152810
[TBL] [Abstract][Full Text] [Related]
17. Copper biology.
Tsang T; Davis CI; Brady DC
Curr Biol; 2021 May; 31(9):R421-R427. PubMed ID: 33974864
[TBL] [Abstract][Full Text] [Related]
18. The molecular mechanisms of cuproptosis and its relevance to cardiovascular disease.
Wang D; Tian Z; Zhang P; Zhen L; Meng Q; Sun B; Xu X; Jia T; Li S
Biomed Pharmacother; 2023 Jul; 163():114830. PubMed ID: 37150036
[TBL] [Abstract][Full Text] [Related]
19. Role of cuproptosis in understanding diseases.
Cao S; Wang Q; Sun Z; Zhang Y; Liu Q; Huang Q; Ding G; Jia Z
Hum Cell; 2023 Jul; 36(4):1244-1252. PubMed ID: 37154876
[TBL] [Abstract][Full Text] [Related]
20. Copper and Zinc Particles as Regulators of Cardiovascular System Function-A Review.
Kitala K; Tanski D; Godlewski J; Krajewska-Włodarczyk M; Gromadziński L; Majewski M
Nutrients; 2023 Jul; 15(13):. PubMed ID: 37447366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
